Patent · US Active

2-azaspiro[3.4]octane derivatives as M4 agonists

US11820778B2 · kind B2 · utility

0Cited by

0References

30Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Amy Calhoun · Cambridge, US
Xin Chen · Lexington, US
Kevin Matthew Gardinier · Fishers, US
Edward Charles Hall · Cambridge, US
Keith Jendza · Boston, US
Nancy LABBE-GIGUERE · Arlington, US
James Neef · Stow, US
Daniel Steven Palacios · Cambridge, US
Ming Qian · Watertown, US
Michael David Shultz · Lexington, US
Christopher Thomson · Billingshurst, GB
Kate Yaping WANG · Boxborough, US
Fan Yang · Brookline, US

Key dates

Filing date	Aug 8, 2022
Grant date	Nov 21, 2023
Priority date	—
Expiry date	Aug 8, 2042

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P25/18
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.